A5084931223- Genetic Neurodegenerative Diseases
- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Ion channel regulation and function
- Liver Disease and Transplantation
- Myasthenia Gravis and Thymoma
- Cardiac electrophysiology and arrhythmias
- Muscle Physiology and Disorders
- Mitochondrial Function and Pathology
- Parkinson's Disease Mechanisms and Treatments
- Gastric Cancer Management and Outcomes
- Marine and fisheries research
- Peripheral Neuropathies and Disorders
- Cardiomyopathy and Myosin Studies
- Neuroscience and Neuropharmacology Research
- RNA Research and Splicing
- Gastrointestinal disorders and treatments
- Cancer Treatment and Pharmacology
- Parkinson's Disease and Spinal Disorders
- Organ Transplantation Techniques and Outcomes
- Ultrasound and Hyperthermia Applications
- Metastasis and carcinoma case studies
- Antifungal resistance and susceptibility
- Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
Saitama Red Cross Hospital
2014-2025
Oita University
2018-2025
Osaka University
2015-2024
Osaka University Hospital
2012-2024
Keio University
1987-2024
Kubota (Japan)
2008-2024
Toho University Ohashi Medical Center
2024
Toho University
2005-2024
Tokyo Medical University
2024
Mirai Hospital
2021-2024
The objective of this study is to investigate predictive factors and long-term outcomes de novo portal vein thrombosis (PVT) in cirrhosis.The incidence PVT (diagnosed by Doppler ultrasound) prognosis were examined 150 patients with virus-related cirrhosis but without at baseline.PVT developed 28% (42/150), cumulative 12.8%, 20%, 38.7% 1, 5, 8-10 years, respectively. baseline flow volume the largest collateral vessel was an independent risk factor for (hazard ratio, 3.922; 95% confidence...
Abstract Myotonic dystrophy (DM) is caused by the expression of mutant RNAs containing expanded CUG repeats that sequester muscleblind-like (MBNL) proteins, leading to alternative splicing changes. Cardiac alterations, characterized conduction delays and arrhythmia, are second most common cause death in DM. Using RNA sequencing, here we identify novel alterations DM heart samples, including a switch from adult exon 6B towards fetal 6A cardiac sodium channel, SCN5A . We find MBNL1 regulates...
Myotonic dystrophy type 1 (DM1) is a debilitating multisystemic disorder caused by CTG repeat expansion in the DMPK gene. Aberrant splicing of several genes has been reported to contribute some symptoms DM1, but cause muscle weakness DM1 and elevated Ca2+ concentrations cultured DM cells unknown. Here, we investigated alternative mRNAs two major proteins sarcoplasmic reticulum, ryanodine receptor (RyR1) sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) or 2. The fetal variants, ASI(-)...
The use of stem cells has enabled the successful generation simple organs. However, anatomically complicated organs such as kidney have proven more refractory to stem-cell-based regenerative techniques. Given limits allogenic organ transplantation, an ultimate therapeutic solution is establish self-organs from autologous and transplant them syngrafts back into donor patients. To this end, we striven in vitro factory build up complex structures adult by using a target organ. Cultivation human...
The phenotypic modulation of vascular smooth muscle cells (VSMCs) from the differentiated state to dedifferentiated one is critically involved in development and progression atherosclerosis. Although many cytokines growth factors have been reported as atherogenic factors, critical pathogens for inducing atherosclerosis remain unknown, largely because proper examining systems them not developed. We recently established primary culture visceral SMCs VSMCs which both SMCs, when cultured on...
Background Early fast-acting treatment (EFT) is the aggressive use of therapies such as plasmapheresis, intravenous immunoglobulin and/or high-dose methylprednisolone (IVMP) from early phases treatment. EFT reportedly beneficial for achievement minimal manifestations (MM) or better status with ≤5 mg/day prednisolone (MM5mg), a practical therapeutic target myasthenia gravis (MG). Objective The current study aimed to clarify which specific regimen efficacious and patient characteristics that...
Efgartigimod, which has been well tolerated and efficacious in individuals with generalized myasthenia gravis (MG), is available Japan not only for the treatment of anti-acetylcholine receptor-positive (AChR+) but also anti-muscle-specific receptor tyrosine kinase (MuSK+) seronegative MG. We report details use efgartigimod MG clinical practice Japan.
The molecular mechanisms behind phenotypic modulation of smooth muscle cells (SMCs) remain unclear. In our recent paper, we reported the establishment novel culture system gizzard SMCs (Hayashi, K., H. Saga, Y. Chimori, K. Kimura, Yamanaka, and Sobue. 1998. J. Biol. Chem. 273: 28860–28867), in which insulin-like growth factor-I (IGF-I) was most potent for maintaining differentiated SMC phenotype, IGF-I triggered phosphoinositide 3-kinase (PI3-K) protein kinase B (PKB(Akt)) pathway. Here,...
32 patients with uncontrollable genital bleeding resulting from postpartum haemorrhage (n = 15) or malignant neoplasms 17) were treated by arterial embolization therapy on an emergency basis. The 15 responded dramatically to treatment embolization. Follow-up computed tomography magnetic resonance studies in 12 cases showed haematomas the pelvic extraperitoneal space, but most then reduced size disappeared spontaneously. In two large haematomas, laparotomy was required. No serious...
Severe hypercalcemia (serum calcium, 4.37-4.84 nmol/L) was found in a 70-yr-old man who had small cell carcinoma of the lung with multiple metastases. The plasma immunoreactive PTH concentration markedly elevated, as measured three different assays [N-terminal PTH, 4,650 ng/L (normal, 230-630); midregion 13,850 180-560); C-terminal 9,900 less than 1,300)], but at autopsy parathyroid glands were histologically normal. liver metastasis 503.5 ng/g wet wt (normal liver, 4.2-5.9), and tumor...
Background : The aim of this study was to assess the effect preoperative and postoperative synbiotic treatment in hepatectomy patients with or without liver cirrhosis. Methods Sixty‐one hepatic cancer were assigned randomly receive either oral synbiotics that consisted Bifidobacterium, Lactobacillus , galactooligosaccharides no (control) preoperatively for 14 days postoperatively 11 days. Infectious complications, intestinal mucosal integrity as measured by serum diamine oxidase (DAO)...
Myotonic dystrophy type 1 (DM1) is a multi-systemic disorder caused by CTG trinucleotide repeat expansion (CTGexp) in the DMPK gene. In skeletal muscle, nuclear sequestration of alternative splicing factor muscleblind-like (MBNL1) explains majority defects observed HSALR transgenic mouse model which expresses pathogenic range CTGexp. present study, we addressed possibility that MBNL1 CUGexp RNA also contributes to mammalian brain. We examined from brains homozygous Mbnl1ΔE3/ΔE3 knockout mice...
<h3>Objective:</h3> To identify other causative genes for Andersen–Tawil syndrome, which is characterized by a triad of periodic paralysis, cardiac arrhythmia, and dysmorphic features. syndrome caused in majority cases mutations <i>KCNJ2</i>, encodes the Kir2.1 subunit inwardly rectifying potassium channel. <h3>Methods:</h3> The proband exhibited episodic flaccid weakness characteristic TU-wave pattern, both suggestive but did not harbor <i>KCNJ2</i> mutations. We performed exome capture...
Myotonic dystrophy type 1 and 2 (DM1, DM2) are caused by expansions of CTG CCTG repeats, respectively. RNAs containing expanded CUG or CCUG repeats interfere with the metabolism other through titration Muscleblind-like (MBNL) RNA binding proteins. DM2 follows a more favorable clinical course than DM1, suggesting that specific modifiers may modulate DM severity. Here, we report rbFOX1 protein binds to but not repeats. Interestingly, competes MBNL1 for overexpression partly releases from...
Abstract Background: Hyperactivation of the phosphatidylinositol-3-kinase (PI3K) pathway can occur due to PIK3CA mutations, present in ~40% patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2—) ABC. SOLAR-1, a Phase 3 randomized, double-blind trial (NCT02437318), investigated efficacy and safety ALP (α-specific PI3K inhibitor) + FUL pts HR+, HER2— ALP+FUL met primary endpoint by significantly extending progression-free survival (PFS)...
<h3>Importance</h3> Repeat expansion of CGG in<i>LRP12</i>has been identified as the causative variation oculopharyngodistal myopathy (OPDM). However, to our knowledge, clinicopathologic features OPDM with repeat in<i>LRP12</i>(hereafter referred OPDM_LRP12) remain unknown. <h3>Objective</h3> To identify and characterize patients OPDM_LRP12<i>.</i> <h3>Design, Setting, Participants</h3> This case series included 208 a clinical or diagnosis oculopharyngeal muscular dystrophy (OPDM) from...
Abstract Objective Eculizumab and ravulizumab are complement protein C5 inhibitors, showing efficacy tolerability for patients with anti‐acetylcholine receptor‐positive (AChR+) generalized myasthenia gravis (gMG) in phase 3 clinical trials subsequent analyses. The purpose of the present study was to evaluate significance eculizumab switching refractory AChR+ gMG real‐world experience. Methods Among database Japan MG registry survey 2021, we studied who received eculizumab. We also evaluated...